BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

688 related articles for article (PubMed ID: 36591282)

  • 21. Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer.
    Zhang Y; Ware MB; Zaidi MY; Ruggieri AN; Olson BM; Komar H; Farren MR; Nagaraju GP; Zhang C; Chen Z; Sarmiento JM; Ahmed R; Maithel SK; El-Rayes BF; Lesinski GB
    Mol Cancer Ther; 2021 Jan; 20(1):150-160. PubMed ID: 33037138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Upregulation of amplified in breast cancer 1 contributes to pancreatic ductal adenocarcinoma progression and vulnerability to blockage of hedgehog activation.
    Li L; Bao J; Wang H; Lei JH; Peng C; Zeng J; Hao W; Zhang X; Xu X; Yu C; Deng CX; Chen Q
    Theranostics; 2021; 11(4):1672-1689. PubMed ID: 33408774
    [No Abstract]   [Full Text] [Related]  

  • 23. DJ-1 promotes invasion and metastasis of pancreatic cancer cells by activating SRC/ERK/uPA.
    He X; Zheng Z; Li J; Ben Q; Liu J; Zhang J; Ji J; Yu B; Chen X; Su L; Zhou L; Liu B; Yuan Y
    Carcinogenesis; 2012 Mar; 33(3):555-62. PubMed ID: 22223849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma.
    Chen D; Huang H; Zang L; Gao W; Zhu H; Yu X
    Front Immunol; 2021; 12():728062. PubMed ID: 34691034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inactivation of APC Induces CD34 Upregulation to Promote Epithelial-Mesenchymal Transition and Cancer Stem Cell Traits in Pancreatic Cancer.
    Hsieh MJ; Chiu TJ; Lin YC; Weng CC; Weng YT; Hsiao CC; Cheng KH
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32586050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF-1.
    Steins A; van Mackelenbergh MG; van der Zalm AP; Klaassen R; Serrels B; Goris SG; Kocher HM; Waasdorp C; de Jong JH; Tekin C; Besselink MG; Busch OR; van de Vijver MJ; Verheij J; Dijk F; van Tienhoven G; Wilmink JW; Medema JP; van Laarhoven HW; Bijlsma MF
    EMBO Rep; 2020 May; 21(5):e48780. PubMed ID: 32173982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer.
    Harris NLE; Vennin C; Conway JRW; Vine KL; Pinese M; Cowley MJ; Shearer RF; Lucas MC; Herrmann D; Allam AH; Pajic M; Morton JP; ; Biankin AV; Ranson M; Timpson P; Saunders DN
    Oncogene; 2017 Jul; 36(30):4288-4298. PubMed ID: 28346421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway.
    Chen ST; Kuo TC; Liao YY; Lin MC; Tien YW; Huang MC
    Oncogene; 2018 Nov; 37(46):6041-6053. PubMed ID: 29993037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment.
    Gomez-Chou SB; Swidnicka-Siergiejko AK; Badi N; Chavez-Tomar M; Lesinski GB; Bekaii-Saab T; Farren MR; Mace TA; Schmidt C; Liu Y; Deng D; Hwang RF; Zhou L; Moore T; Chatterjee D; Wang H; Leng X; Arlinghaus RB; Logsdon CD; Cruz-Monserrate Z
    Cancer Res; 2017 May; 77(10):2647-2660. PubMed ID: 28249896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
    Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
    J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer.
    Asuthkar S; Stepanova V; Lebedeva T; Holterman AL; Estes N; Cines DB; Rao JS; Gondi CS
    Mol Biol Cell; 2013 Sep; 24(17):2620-32. PubMed ID: 23864708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
    Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
    Front Immunol; 2021; 12():648917. PubMed ID: 33777046
    [No Abstract]   [Full Text] [Related]  

  • 34. Prognostic significance and immune infiltration of microenvironment-related signatures in pancreatic cancer.
    Lu Q; Zhang Y; Chen X; Gu W; Ji X; Chen Z
    Medicine (Baltimore); 2021 Mar; 100(12):e24957. PubMed ID: 33761652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pancreatic stellate cells and pancreas cancer: current perspectives and future strategies.
    Haqq J; Howells LM; Garcea G; Metcalfe MS; Steward WP; Dennison AR
    Eur J Cancer; 2014 Oct; 50(15):2570-82. PubMed ID: 25091797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MiR-301a transcriptionally activated by HIF-2α promotes hypoxia-induced epithelial-mesenchymal transition by targeting TP63 in pancreatic cancer.
    Zhang KD; Hu B; Cen G; Yang YH; Chen WW; Guo ZY; Wang XF; Zhao Q; Qiu ZJ
    World J Gastroenterol; 2020 May; 26(19):2349-2373. PubMed ID: 32476798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypoxia and pancreatic ductal adenocarcinoma.
    Yamasaki A; Yanai K; Onishi H
    Cancer Lett; 2020 Aug; 484():9-15. PubMed ID: 32380129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biomaterial substrate-derived compact cellular spheroids mimicking the behavior of pancreatic cancer and microenvironment.
    Wong CW; Han HW; Tien YW; Hsu SH
    Biomaterials; 2019 Aug; 213():119202. PubMed ID: 31132644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of PDAC subtype heterogeneity and therapy response.
    Espinet E; Klein L; Puré E; Singh SK
    Trends Cancer; 2022 Dec; 8(12):1060-1071. PubMed ID: 36117109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. YAP1-mediated pancreatic stellate cell activation inhibits pancreatic cancer cell proliferation.
    Xiao Y; Zhang H; Ma Q; Huang R; Lu J; Liang X; Liu X; Zhang Z; Yu L; Pang J; Zhou L; Liu T; Wu H; Liang Z
    Cancer Lett; 2019 Oct; 462():51-60. PubMed ID: 31352078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.